Delay of initiation of adjuvant chemotherapy in patients with early breast cancer: causes and consequences

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Adjuvant chemotherapy (ACT) for breast cancer (BC) has been successfully used as part of complex treatment for several decades. The concept of BC as a systemic disease has made it possible to develop optimal treatment algorithms, including both local methods of disease control, such as surgery and radiation therapy, and systemic drug treatment. The effectiveness of adjuvant systemic therapy in increasing overall and relapse-free survival is not in doubt, however, the optimal timing of initiation of chemotherapy after radical surgical treatment has not been reliably determined to date. Many factors, such as age, comorbidity, type of surgery, and patient compliance with treatment, can delay chemotherapy. We analyzed the largest studies in this area to gain insight into what may cause delays in adjuvant treatment and the long-term consequences of such delays for the patient.

Толық мәтін

Рұқсат жабық

Авторлар туралы

G. Dashyan

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Хат алмасуға жауапты Автор.
Email: dgarik@mail.ru
ORCID iD: 0000-0001-6183-9764
SPIN-код: 6989-7148
Scopus Author ID: 17344871400

Dr. Sci. (Med.), Head of Oncology Department № 1 (Surgical Methods for the Treatment of Tumors of the Breast, Skin and Soft Tissues)

Ресей, St. Petersburg

V. Konstantinova

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0001-9650-7305
Ресей, St. Petersburg

E. Dzhelialov

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0002-2571-243X
SPIN-код: 7261-2325
Ресей, St. Petersburg

R. Akhmedov

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0003-3348-4251
Ресей, St. Petersburg

Yu. Semiletova

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0001-5706-250X
Ресей, St. Petersburg

A. Zhurov

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0009-0004-7511-2952
Ресей, St. Petersburg

A. Tyusenko

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0003-0689-6058
SPIN-код: 9223-5741
Ресей, St. Petersburg

A. Olchonova

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
Ресей, St. Petersburg

I. Pavlikova

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0002-1753-6296
Ресей, St. Petersburg

A. Belousov

Clinic of High Medical Technologies n.a. N.I. Pirogov, St. Petersburg State University

Email: dgarik@mail.ru
ORCID iD: 0000-0002-2274-8170
Ресей, St. Petersburg

Әдебиет тізімі

  1. Всемирная организация здравоохранения, 2023 г. [The World Health Organization 2023. (In Russ.)].
  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. doi: 10.1016/S0140-6736(05)66544-0.
  3. Engel J., Eckel R., Kerr J., et al. The process of metastasisation for breast cancer. Eur J Cancer. 2003;39(12):1794–806. doi: 10.1159/000323483.
  4. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastas Rev. 1990;9(3):171–74. doi: 10.1007/BF00046358.
  5. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11–12):1727–33.
  6. Fisher B., Gunduz N., Coyle J., et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Canc. Res. 1989;49(8):1996–2001. Heppner GH: In vitro studies on cell-mediated.
  7. Heppner G.H. In vitro studies on cell-mediated immunity following surgery in mice sensitized to syngeneic mammary tumors. Int J Canc. 1972;9(1):119–25. doi: 10.1002/ijc.2910090114.
  8. Fisher B., Gunduz N., Saffer E.A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Canc Res. 1983;43(4):1488–92.
  9. Kupstas A.R., Hoskin T.L., Day C.N., et al. Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival: a national cancer database analysis. Ann Surg Oncol. 2019;26(10):3240–9. doi: 10.1245/s10434-019-07566-7.
  10. Downing A., Twelves C., Forman D., et al. Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast J. 2014;20(1):29–36. doi: 10.1111/tbj.12209.
  11. Chavez-MacGregor M., Clarke C.A., Lichtensz-tajn D.Y., et al. Delayed initiation of adjuvant chemotherapy among patients with breast Cancer. JAMA. Oncol. 2016;2(3):322–29. doi: 10.1001/jamaoncol.2015.3856.
  12. Nurgalieva Z.Z., Franzini L., Morgan R.O., et al. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol. 2013;30(1):419. doi: 10.1007/s12032-012-0419-1.
  13. Farolfi A., Scarpi E., Rocca A., et al. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer. 2015;51(14):1874–81. doi: 10.1016/j.ejca.2015.07.003.
  14. Shannon C., Ashley S., Smith I.E. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J ClinOncol. 2003;21(20):3792–97. doi: 10.1200/JCO.2003.01.073.
  15. Jara Sanchez C., Ruiz A., Martin M., et al. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM)[J]. Breast Cancer Res Treat. 2007;101(2):215–23. doi: 10.1007/s10549-006-9282-0.
  16. Cold S., During M., Ewertz M., et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)[J]. Br J Cancer. 2005;93(6):627–32. doi: 10.1038/sj.bjc.6602734.
  17. Yu K.D., Huang S., Zhang J.X., et al. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC. Cancer. 2013;13:240. doi: 10.1186/1471-2407-13-240.
  18. Raphael M.J., Biagi J.J., Kong W., et al. The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2016; 160(1):17–28. doi: 10.1007/s10549-016- 3960-3.
  19. Biagi J.J., Raphael M.J., King W.D., et al. The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): a systematic review and meta-analysis. JAMA. 2011;29(15):1128. doi: 10.1200/jco.2011.29.15_suppl.1128.
  20. Lohrisch C., Paltiel C., Gelmon K., et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-s tage breast cancer. J Clin Oncol. 2006;24(30):4888–94. doi: 10.1200/JCO.2005.01.6089.
  21. Gagliato D.M., Gonzalez-Angulo A.M., Lei X., et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014;32(8):735–44. doi: 10.1200/JCO.2013.49.7693.
  22. Morante Z., Ruiz R., Araujo J.M., et al. Impact of the delayed initiation of adjuvant chemotherapy in the outcome of triple negative breast Cancer. Clin Breast Cancer. 2021;21(3):239–46 e234. doi: 10.1016/j.clbc.2020.09.008.
  23. Ashok Kumar P., Paulraj S., Wang D., et al. Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study. J Cancer Res Clin Oncol. 2021; 147(8):2447–58. doi: 10.1007/s00432-021- 03525-6.
  24. He X., Ye F., Zhao B., et al. Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: a systematic review and meta-analysis involving 186982 patients. PLoS One. 2017;12(3):e0173862. doi: 10.1371/journal.pone.0173862.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2023

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>